144 related articles for article (PubMed ID: 37771164)
21. Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial.
Coleman RL; Lorusso D; Oaknin A; Cecere SC; Denys H; Colombo N; van Gorp T; Konner JA; Romeo Marin M; Harter P; Murphy C; Wang Y; Esteves B; Method M; Matulonis U
Int J Gynecol Cancer; 2024 Jun; ():. PubMed ID: 38858103
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic strategies targeting folate receptor α for ovarian cancer.
Mai J; Wu L; Yang L; Sun T; Liu X; Yin R; Jiang Y; Li J; Li Q
Front Immunol; 2023; 14():1254532. PubMed ID: 37711615
[TBL] [Abstract][Full Text] [Related]
23. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.
Moore KN; Martin LP; O'Malley DM; Matulonis UA; Konner JA; Vergote I; Ponte JF; Birrer MJ
Future Oncol; 2018 Jan; 14(2):123-136. PubMed ID: 29098867
[TBL] [Abstract][Full Text] [Related]
24. Mirvetuximab soravtansine in platinum-resistant recurrent ovarian cancer with high folate receptor-alpha expression: a cost-effectiveness analysis.
Zhu Y; Lin Y; Liu K; Zhu H
J Gynecol Oncol; 2024 Mar; ():. PubMed ID: 38576343
[TBL] [Abstract][Full Text] [Related]
25. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
Moore KN; Borghaei H; O'Malley DM; Jeong W; Seward SM; Bauer TM; Perez RP; Matulonis UA; Running KL; Zhang X; Ponte JF; Ruiz-Soto R; Birrer MJ
Cancer; 2017 Aug; 123(16):3080-3087. PubMed ID: 28440955
[TBL] [Abstract][Full Text] [Related]
26. Mirvetuximab soravtansine: A breakthrough in targeted therapy for platinum-resistant ovarian cancer.
Kokori E; Olatunji G; Komolafe R; Abraham IC; Ukoaka B; Samuel O; Ayodeji A; Ogunbowale I; Ezenwoba C; Aderinto N
Medicine (Baltimore); 2024 May; 103(20):e38132. PubMed ID: 38758856
[TBL] [Abstract][Full Text] [Related]
27. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
Ponte JF; Ab O; Lanieri L; Lee J; Coccia J; Bartle LM; Themeles M; Zhou Y; Pinkas J; Ruiz-Soto R
Neoplasia; 2016 Dec; 18(12):775-784. PubMed ID: 27889646
[TBL] [Abstract][Full Text] [Related]
28. Mirvetuximab Soravtansine Combination Yields Encouraging Response Rates in Ovarian Cancer.
Fowler M
Oncology (Williston Park); 2020 Jul; 34(7):250. PubMed ID: 32674207
[TBL] [Abstract][Full Text] [Related]
29. A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer.
Yam C; Rauch GM; Rahman T; Karuturi M; Ravenberg E; White J; Clayborn A; McCarthy P; Abouharb S; Lim B; Litton JK; Ramirez DL; Saleem S; Stec J; Symmans WF; Huo L; Damodaran S; Sun R; Moulder SL
Invest New Drugs; 2021 Apr; 39(2):509-515. PubMed ID: 32984932
[TBL] [Abstract][Full Text] [Related]
30. Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer.
Gonzalez-Ochoa E; Veneziani AC; Oza AM
Clin Med Insights Oncol; 2023; 17():11795549231187264. PubMed ID: 37528890
[TBL] [Abstract][Full Text] [Related]
31. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
Miao M; Deng G; Luo S; Zhou J; Chen L; Yang J; He J; Li J; Yao J; Tan S; Tang J
Gynecol Oncol; 2018 Feb; 148(2):286-290. PubMed ID: 29248198
[TBL] [Abstract][Full Text] [Related]
32. Mirvetuximab soravtansine superior to chemotherapy in platinum-resistant epithelial ovarian cancer.
Sidaway P
Nat Rev Clin Oncol; 2024 Feb; 21(2):83. PubMed ID: 38114788
[No Abstract] [Full Text] [Related]
33. Integrating antibody drug conjugates in the management of gynecologic cancers.
Chelariu-Raicu A; Mahner S; Moore KN; Lorusso D; Coleman RL
Int J Gynecol Cancer; 2023 Mar; 33(3):420-429. PubMed ID: 36878560
[TBL] [Abstract][Full Text] [Related]
34. Antibody-drug conjugates for the treatment of ovarian cancer.
Calo CA; O'Malley DM
Expert Opin Biol Ther; 2021 Jul; 21(7):875-887. PubMed ID: 32463296
[TBL] [Abstract][Full Text] [Related]
35. The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials.
Guo C; Yan C; Qu L; Du R; Lin J
Arch Gynecol Obstet; 2021 Feb; 303(2):285-311. PubMed ID: 33222040
[TBL] [Abstract][Full Text] [Related]
36. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
[TBL] [Abstract][Full Text] [Related]
37. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
38. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R
BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028
[TBL] [Abstract][Full Text] [Related]
39. Antibody-drug conjugates for ovarian cancer: current clinical development.
Stewart D; Cristea M
Curr Opin Obstet Gynecol; 2019 Feb; 31(1):18-23. PubMed ID: 30531606
[TBL] [Abstract][Full Text] [Related]
40. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
Patel A; Kalachand R; Busschots S; Doherty B; Kapros E; Lawlor D; Hall N; Stordal BK
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD008766. PubMed ID: 35866378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]